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INTRODUCTION
Purpura	 is	defined	as	a	visible	hemorrhage	 in	 the	skin	or	
mucosa	that	is	not	evanescent	upon	pressure.	Proper	classification	
provides a better patient approach due to the multiple diagnoses of 
purpura.	Purpuras	can	be	classified	by	size,	morphology,	pathophy-
siology,	and	other	characteristics	(Table	1).
Regarding	morphology,	 retiform	purpura	should	be	diffe-
rentiated from livedo reticularis and livedo racemosa. These conditions 
have	 a	 similar	morphological	 appearance,	 characterized	 as	 viola-
ceous	macules	in	a	net-like,	arborized,	or	starry	form	but	they	differ	
in	pathophysiology	(Chart	1).
The clinical course varies according to the etiology. Macular 
purpura or non-palpable purpura heals faster and exhibits a col-
or	transition	from	red-blue	to	violaceous,	green,	yellow,	or	brown	
due	 to	extravasation	of	 erythrocytes	and	 few	 inflammatory	cells.1 
Palpable	purpura	takes	longer	to	heal	due	to	the	presence	of	inflam-
matory cells and immune complex deposits that lead to vascular 
occlusion.1
Purpura	 has	 a	 long	 list	 of	 differential	 diagnoses,	 which	
differ particularly in their pathophysiology. One way to approach 
purpura	 is	by	answering	 the	question,	“Is	 the	patient	bleeding?”,	
since	some	bleeding	disorders	require	urgent	treatment	(Figure	1).	
The purpose of this review is to describe some of the differential 
diagnoses and their physiopathogenic mechanisms to provide a bet-
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table 1: Purpura classification
Size Morphology Characteristics
≤	4mm	=	petechiae Retiform Inflammatory
5 to 9mm = macule Non-retiform Non-inflammatory
≥	1cm	=	ecchymosis Livedo reticularis
Livedo racemosa
Source:	Piette	WW,	2012.1
Source:	Wysong	A,	et al, 2011.16 
chart 1: Livedo reticularis, livedo racemosa, and retiform purpu-
ra characteristics
Pathophysiology Topography
Livedo reticularis Low	blood	flow	due	
to low output state.
Lower extremities
Livedo racemosa Irregular	blood	flow	
due to mechanical 
obstruction.
Trunk	and	lower	
extremities
Retiform purpura Purpura and necro-
sis due to venous 
occlusion.
Variable	
Figure 1: Purpura: diagnostic algorithm
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ter patient approach and guide treatment. This article will discuss 
pigmented purpuras and some cutaneous vascular occlusion syn-
dromes. Although vasculitis is part of the differential diagnoses, it 
will not be discussed in this review.
Pigmented purpuras
Pigmented purpuras, also known as chronic pigmented 
purpuric dermatosis, purpura simplex, and capillaritis, among oth-
ers, encompasses five major clinical variants, including Schamberg’s 
purpura, purpura annularis telangiectodes of Majocchi, pigment-
ed purpuric lichenoid dermatitis of Gougerot and Blum, eczema-
tid-like purpura of Doucas and Kapetanakis, and lichen aureus.1-4 
Each condition is associated with different triggers, which are diffi-
cult to establish in practice and do not appear to have therapeutic or 
prognostic implications.3,4 
Capillaritis is associated with many triggers, including ve-
nous hypertension, exercise, pregnancy, frail capillaries, drug tox-
icity from acetaminophen, aspirin, hydralazine, and thiamine, and 
hyperactive substances such as textiles, colorants, and alcohol.2,3 Id-
iopathic capillaritis is the most common form, since most cases are 
not associated with a specific trigger.4
Epidemiological data are lacking. However, a 5-fold in-
creased prevalence is noted in men compared to women. The con-
dition predominantly affects adults 40 to 60 years of age.2,5 Some 
variants predominate in children and young adults.3-5
The physiopathogenesis is unknown, but the condition is 
believed to be due to a cutaneous hypersensitivity reaction that 
causes capillary fragility and permeability, leading to erythrocyte 
extravasation and hemosiderin deposits noted on biopsy.1,2,6 The 
following three main pathogenic theories have been described ac-
cording to histological data: vascular fragility, humoral immunity, 
and cellular immunity.2,3 
Pigmented purpuras present as petechiae or pigmented ma-
cules on distal lower extremities.1-4 These lesions can be generalized, 
due to self-limiting viral infection, or localized. All variants have 
specific distinguishing clinical characteristics (Chart 2). 
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NPH: nocturnal paroxysmal hemoglobinuria; TTP: thrombotic thrombocytopenic purpura; APS: antiphospholipid syndrome; HIT: heparin-induced thrombocytopenia; ITP: ldiopathic 
thrombocytopenic purpura; NSAID: non-steroidal anti-inflammatory drugs; DIC: disseminated intravascular coagulation 
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Source:	Díaz	Molina	VL	et al.,	2009	2; Sardana K et al.,	2004	3;	Allevato	MA,	2007	4;	Karadag	AS	et al.,	2013	5,	and	Hoesly	FJ	et al,,	2009. 7
chart 2: Pigmented purpuras
Clinical appearance Topography Histology
Schamberg’s	Purpura Purpuric	macules	forming	large	plaques	
that	acquire	a	brownish	color	described	
as	“Cayenne	pepper	grains”
Lower limbs 
(pretibial)
Perivascular	lymphocytic	infiltrate,	
with erythrocyte extravasation and 
hemosiderin deposit
Eczematid-like	purpura	of	
Doucas	and	Katepanakis
Eczematous	changes	with	lichenification Lower limbs
Purpura annularis telangiec-
todes	of	Majocchi
Symmetric	annular	brown-red	macules,	
with a clear atrophic center
Lower limbs
Geugerot	and	Blum’s	Disease lichenified	orange-red	or	purpuric	
plaques	
Legs,	thighs,	
trunk,	and	occa-
sionally arms
Lichen aureus Purpuric macules with orange or golden 
lichenoid papules
Lower limbs Same characteristics as lichenoid 
band-like	dermal	lymphocyte	
infiltrate
Linear capillaritis Similar to lichen aureus with linear 
pattern
Lower limbs Same as other pigmented purpuras
Schamberg’s purpura 
This	condition	is	also	known	as	progressive	or	chronic	pur-
puric	 dermatosis.	 Schamberg’s	 purpura	 predominates	 in	 men	 in	
their 50s and is associated with viral infections. 2 The condition typ-
ically	involves	the	pretibial	region	and	extends	proximally,	sparing	
the	 face,	 palmo-plantar	 regions.	 3	 Schamberg’s	 purpura	 typically	
presents	as	purpuric	macules	forming	large	plaques	that	acquire	a	
brownish	color	described	as	“Cayenne	pepper	grains”.2,3 The lesions 
tend to be asymptomatic but are sometimes mildly pruritic.3
Eczematid-like Purpura of Doucas and Katepanakis
Eczematid-like	purpura	or	itching	purpura	is	described	as	
a	variant	of	Schamberg’s	purpura	3,	5 that typically affects men.5 The 
condition	 is	characterized	by	eczematous	alterations	on	 the	 lower	
extremities	associated	with	pruritus	and	secondary	 lichenification	
in patients who scratch the purpura.4,5 Similar to other types of cap-
illaritis,	the	condition	has	a	chronic	course	with	spontaneous	remis-
sion.3,5 This purpura has been associated with an allergic reaction 
to textiles.3,4 
Purpura annularis telangiectodes of Majocchi
This	condition	 is	 characterized	by	symmetric	 lesions,	pre-
dominantly affecting the lower extremities with proximal extension 
to	the	buttocks.3 The lesions appear as brownish-red purpuric mac-
ules with an annular or arciform pattern2 and clear center3 that can 
become atrophic.7	The	lesions	can	be	confused	with	vasculitis,	so	it	
is	important	to	take	this	into	account.4 The	etiology	is	unclear,	but	
the	condition	is	associated	with	pregnancy	and	venous	insufficiency	
that worsens with textile friction.2,4 It mainly affects adolescent girls 
and young adult women.4,7 The lesions typically display a chronic 
asymptomatic	course,	but	can	be	associated	with	pruritus.2,4
Gougerot and Blum’s disease
Lichenoid	 purpuric	 dermatosis	 or	 Gougerot	 and	 Blum’s	
disease affects adults between 40 and 60 years of age.2 The condition 
is	characterized	by	lichenified	plaques	with	an	orangish-red	or	pur-
plish color on the anterior regions of lower extremities (lower legs 
and	thighs),	trunk,	and	occasionally	arms.2,	4,8	When	single,	a	lesion	
can	mimic	Kaposi’s	sarcoma.2,4 Some cases may be associated with 
mycosis fungoides.2,4 
Lichen aureus
Also	called	purpuric	 lichen,	 lichen	aureus	 is	named	for	to	
its golden color.3	Affecting	young	adults	between	20	and	30	years	
of	age,	 it	 is	characterized	by	typically	unilateral	orange	or	golden	
purpuric macules with lichenoid papules on the lower extremi-
ties.2-4	The	lesions	are	often	chronic,	lasting	between	3	months	and	
20 years.4	The	condition	may	be	associated	with	drugs,	trauma,	or	
venous stasis.4	 It	 shares	histological	 characteristics,	 such	as	eryth-
rocyte	extravasation	and	perivascular	infiltrate,	with	other	types	of	
capillaritis	 but	 characteristically	 presents	 a	 band-like	 lymphocyte	
infiltrate	below	a	fine	Grenz	zone4 that distinguishes it from other 
types of capillaritis on histopathology. 
Linear capillaritis 
Linear	capillaritis,	or	pigmented	purpuric	dermatosis,	looks	
similar	to	lichen	aureus	with	a	linear	distribution.	However,	histo-
logically,	 the	 condition	does	not	present	with	 lichenoid	 infiltrate.2 
The	condition	is	five	times	more	common	in	men	than	women	and	
appears on the lower extremities.9
Diagnosis, treatment, and prognosis 
Diagnosis is clinical. Pigmented purpuras typically exhib-
it	an	asymptomatic	course	with	minimal	pruritus,	occasional	pain,	
and	 normal	 laboratory	 findings.2	 Some	 cases	 require	 a	 biopsy	 to	
distinguish	 them	 from	other	entities,	 such	as	vasculitis.	On	histo-
pathology,	pigmented	purpuras	exhibit	a	perivascular	lymphocytic	
infiltrate,	vascular	dilation	with	erythrocyte	extravasation,	and	he-
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specificity.13,17	 Confirmation	 with	 anti-PF2/heparin	 antibodies	 by	
enzyme	immunoassay	(EIA)	is	also	recommended.13 
Treatment is based on discontinuing heparin and using an 
alternative anticoagulant therapy such as a thrombin inhibitor fol-
lowed	by	vitamin	K,	if	needed.12,15,16	Alternative	heparin	is	reserved	
for cases not associated with HIT syndrome.12	Wound	 care,	 pain	
management,	 and	 surgical	 debridement	 and	 skin	 graft	 should	 be	
provided when needed.12,	16 
 Thrombocytopenia secondary to myeloproliferative dis-
orders
Myeloproliferative	 disorders	 are	 characterized	 by	 abnor-
mal proliferation of one or more cell lines on peripheral blood tests. 
The	condition	differs	from	acute	leukemia	and	mainly	affects	young	
women.11 Polycythemia vera and essential thrombocytopenia are the 
most	common	forms	affecting	the	skin.11 These conditions can present 
as	cutaneous	vascular	occlusion	syndromes	in	the	form	of	purpura,	
hematomas,	erythromelalgia,	 livedo reticularis,	Raynaud’s	phenome-
non,	leg	ulcers,	gangrene,	and	thrombophlebitis.11,18,19 The molecular 
pathogenesis	implicated	in	these	diseases	is	poorly	known,	but	mu-
tations	in	the	JAK-2	protein	kinase	gene	have	been	described	in	90	to	
95%	of	patients	with	polycythemia	vera	and	in	50	to	70%	of	patients	
with essential thrombocytopenia.11 Platelet thrombi can be found in 
the	dermal	blood	vessels	of	skin	biopsies.20 Patients with this sign ex-
hibit increased morbidity due to greater thrombotic or hemorrhagic 
potential	or	transformation	to	myelofibrosis	or	leukemia,	compared	
to the general population.21 Treatment is oriented by age and cardio-
vascular	risk.	Anagrelide,	low-dose	aspirin,	hydroxyurea,	and	phle-
botomy have been useful in cases of polycythemia vera.21 
Purpura due to cryoagglutination or cryogelling disorders 
Cryoagglutination	 disorders	 include	 cryoglobulinemias,	
cryofibrinogenemias,	and	cold	agglutinins.11 These syndromes are 
uncommon	 but	 should	 be	 taken	 into	 account	 for	 the	 differential	
diagnosis of vascular occlusion syndromes. Immunoglobulin pre-
cipitates	 at	 temperatures	 below	 4°C	 and	dissolves	 at	 37°C,	 corre-
sponding to cryoglobulinemias.22,23	Cryofibrinogenemias	are	caused	
by	plasma	fibrinogens	that	gel	at	low	temperatures,	and	cold	agglu-
tinin antibodies promote erythrocyte agglutination at cold tempera-
tures,	causing	vascular	occlusion.11 
Cryoglobulinemias	 can	 be	 categorized	 into	 3	 types	 accor-
ding	 to	Brouet’s	 classification	 (Chart	 3).22,23 Type 1 is vascular oc-
clusive,	whereas	types	2	and	3	cause	small	vessel	vasculitis	due	to	
immune	complexes.	These	conditions	affect	women	more	frequently	
(at	a	ratio	of	3:1),	and	the	least	common	cryoglobulinemia	is	type	1.23 
The	etiology	is	based	on	autoimmune	diseases	in	10	to	15%	of	mi-
xed	cryoglobulinemia,	hematologic	neoplasms	in	10	to	15%	of	type	
1	cryoglobulinemia,	and	idiopathic	or	infectious	in	25%	of	cases	of	
mixed cryoglobulinemia.22 The pathogenic mechanism is based on 
monoclonal or polyclonal antibodies secondary to lymphoprolife-
rative or immune stimulation due to infectious or autoimmune di-
seases.23,24	This	section	focuses	on	type	1	cryoglobulinemia,	since	the	
other two types cause vasculitis due to immune complexes. 
Type	1	cryoglobulinemias	affect	skin	and	other	systems	ac-
cording to their pathophysiological mechanism of hyperviscosity 
mosiderin deposits. 
No	standard	therapy	is	available,	but	treatment	should	fo-
cus	on	avoiding	triggers.	Some	treatments,	such	as	topical	steroids,	
griseofulvin,	 pentoxifylline,	 vitamin	 C,	 and	 phototherapy	 have	
reported	success,	with	response	varying	between	patients.5,9,10 Ste-
roid-sparing drugs such as cyclosporine and other immunomodu-
lators such as methotrexate have been used with good results.7 Pa-
tients	can	be	managed	conservatively	with	compressive	stockings	
and lower-extremity lifting to help venous stasis.2,7,9
Pigmented	purpuras	have	a	chronic	benign	course.	However,	
some cases have been associated with T-cell lymphoma.2,3,4,7 These le-
sions	leave	a	post	inflammatory	macule	that	is	difficult	to	treat.2 
 Cutaneous manifestations of microvascular occlusion 
syndromes
Cutaneous manifestations of microvascular occlusion syn-
dromes	are	 characterized	by	 retiform	purpura.	 Inflammatory	and	
non-inflammatory	retiform	purpura	should	be	distinguished	from	
each	other,	and	pertinent	blood	tests	should	be	performed	accord-
ingly	 to	narrow	the	diagnosis	and	provide	appropriate	 treatment,	
given	 the	numerous	differential	diagnoses.	 In	 addition,	 treatment	
varies according to the etiology. The condition is harmful if incor-
rectly	treated	as	an	occlusive	or	inflammatory	syndrome.11 
The differential diagnoses are numerous. This section in-
cludes	some	of	them,	but	the	clinician	should	take	all	other	options	
into account. Pathophysiology is a simple method for classifying the 
conditions and orienting diagnosis.11 
Disorders based on platelet aggregation
Heparin-induced necrosis 
Heparin necrosis is a clinical and pathological entity that re-
quires	previous	heparin	exposure.11-13 The patient presents retiform 
non-inflammatory	necrotizing	purpura	typically	five	to	11	days	after	
exposure,	but	immediately	if	there	has	been	previous	exposure	or	a	
late hypersensitive reaction months later.11,12 Lesions typically begin 
as	painful	erythematous	plaques	that	progress	to	purpura	with	rapid	
necrosis at the site or distal from heparin application with a predilec-
tion	for	the	abdomen,	thighs,	and	legs.11,12	A	platelet	plug	with	peri-
vascular	inflammation	can	be	observed	on	histopathology.14 
The	 condition	 affects	 1	 to	 5%	 of	 adults,	 especially	 mid-
dle-aged	 women	 with	 a	 30%	 incidence	 and	 mortality.11,12,15 The 
following	pathophysiological	mechanisms	have	been	proposed:	1)	
heparin-induced immunity in which IgG antibodies are directed 
against	platelet	factor	4	and	heparin,	causing	platelet	plugging	and	
consumption leading to microvascular occlusion;11-13	2)	Arthus-type	
III	hypersensitivity	reaction;	and	3)	physical	and	mechanical	factors,	
such	as	poor	injection	technique	or	poor	adipose	tissue	circulation.12 
It is mandatory to rule out heparin-induced thrombocyto-
penia or HIT syndrome to guide treatment.16 HIT characteristical-
ly	 presents	with	 thrombocytopenia	 (30-50%	of	 baseline	 value)	 af-
ter heparin exposure.13	Ten	 to	20%	of	patients	 exhibit	 an	elevated	
INR	 value	 and	 hypofibrinogenemia	 consistent	with	 disseminated	
intravascular	coagulation	(DIC)	and	positive	serological	tests,	such	
as	platelet	 serotonin-release	 assay	 (SRA),	which	 is	 considered	 the	
“gold	standard”	for	HIT	diagnosis	with	88%	sensitivity	and	100%	
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FIgure 2: Ecthyma gangrenosum-like due to aspergillosis in a 6-year-
old immunosuppressed patient
or vascular occlusion due to protein precipitation. These conditions 
affect	skin	as	purpura	in	acral	areas	exposed	to	cold	temperatures,	
acrocyanosis,	necrosis,	 cutaneous	ulcers,	Raynaud’s	phenomenon,	
and livedo reticularis.11,22,23	Other	systems	are	affected,	and	symptoms	
include	headache,	confusion,	blurred	vision,	epistaxis,	and	hearing	
loss.22	Skin	ulcers	and	necrosis	are	more	common	in	type	1	cryoglob-
ulinemia than in types 2 or 3.25 Diagnosis is made by clinical suspi-
cion,	presence	of	 serum	cryoglobulins	on	 immunoelectrophoresis,	
immunofixation,	or	immunoblotting	with	98,	54	and	28%	sensitivity	
and	specificity,	respectively,	and	skin	biopsy	exhibiting	non-inflam-
matory thrombosis.23,25
Prognosis	 is	 poor	due	 to	 skin	 severity	 and	 the	 associated	
hematological disorders.22 Reported survival rates vary from 87 to 
94%.26	 Treatment	 should	 be	 individualized	 for	 patients	 based	 on	
their	 comorbidities,	 pathological	 mechanism,	 and	 disease	 severi-
ty.22,23 The most important measure is to avoid exposure to cold. Cor-
ticosteroids,	cyclophosphamide,	or	biologics,	and	plasma	exchange	
for	severe	hyperviscosity	can	be	used	in	individualized	cases.22,23,24 
Vascular occlusion due to microorganisms 
These syndromes cause vascular occlusion due to microor-
ganisms and mainly affect immunosuppressed patients. The group 
includes	ecthyma	gangrenosum,	Lucio’s	leprosy,	opportunistic	fun-
gal	infections,	and	others.	
Ecthyma	 gangrenosum	 is	 characterized	 by	 red	 to	 purple	
macules that form pustules or hemorrhagic ampules that evolve 
into	 necrotic	 ulcers	 within	 12	 to	 24	 hours	 (Figure	 2).27,28	Bacterial 
proliferation	on	subcutaneous	vessel	adventitia	forms	a	thrombus,	
causing	vascular	occlusion	mainly	in	the	buttocks	and	lower	extre-
mities.11,27,29	Absence	of	suppuration	differentiates	ecthyma	gangre-
nosum from pyoderma gangrenosum.27	In	total,	73.65%	of	cases	of	
ecthyma gangrenosum are due to Pseudomonas aeruginosa,	whereas	
17.35%	and	9%	are	due	 to	other	bacteria	and	opportunistic	 fungi,	
respectively.	The	former	cases	should	be	referred	to	as	“ecthyma gan-
grenosum-like”.29	A	compromised	immune	system	is	not	an	obliga-
tory	factor	for	the	disease	but	has	been	reported	in	59%	of	cases.29 
Diagnosis	is	made	with	clinical	suspicion	and	skin	cultures.	Dermal	
necrosis	 with	 neutrophil	 and	 lymphocyte	 inflammatory	 infiltrate	
and	vasculitis	with	occlusive	thrombi	have	been	described	on	skin	
biopsy.28 Gram-negative bacteria can be found on vascular adventi-
tia and perivascular areas. 11 
Lucio’s	leprosy,	also	referred	to	as	necrotizing	erythema	of	
Latapi,	 is	 a	 type	2	 reaction	 that	 corresponds	 to	a	necrotizing	vas-
culitis with thrombosis.30 The condition is found mainly in Mexico 
and	Central	America,	affecting	patients	with	primitive	lepromatous	
leprosy and non-nodular secondary diffuse types.30,31 It has a 5-day 
course initiating on the lower extremities and progressing upward 
until reaching the face.30,31 The lesions begin as purpuric macules 
surrounded	 by	 erythema	 that	 progress	 to	 bullae	 that	 necrotize.31 
Skin	biopsy	findings	depend	on	the	stage	of	evolution	at	which	the	
biopsy	is	obtained,	but	acid-fast	bacilli	with	Fite-Faraco	are	always	
present.30 
The treatment of vascular occlusion syndromes due to mi-
croorganisms	 aims	 to	 improve	 the	 patient’s	 immune	 status	 and	
treat	 infection.	 In	 ecthyma	 gangrenosum,	 antibiotics	 should	 be	
administered empirically with aggressive treatment against fungi 
and	 bacteria	 generally	 with	 ceftazidime,	 ampicillin,	 amoxicillin/
clavulanic	 acid,	 or	 amphotericin	 B.	 In	 addition,	 surgical	 debride-
ment is performed when indicated.29 These patients have a poor 
prognosis	when	associated	with	bacteremia,	resulting	in	20	to	50%	
mortality.28	 For	 Lucio’s	 leprosy,	 thalidomide	 (200	 to	 600mg/day)	
should be administered until a response is observed.30	Alternatively,	
plasmapheresis is provided in non-responsive cases together with 
multibacillary	treatment	and	high-dose	prednisone	(1mg/kg)	with	
monthly tapering.31 
Purpura due to embolization disorders 
Cholesterol embolism
This	condition	is	called	“blue	toe	syndrome”.	The	disorder	
affects	men	 50	years	 or	 older,	 of	whom	15	 to	 20%	have	 a	history	
of	atherosclerotic	disease,	diabetes	mellitus,	hyperlipidemia,	hyper-
*RF	(rheumatoid	factor),	HIV	(human	immunodeficiency	virus),	SLE	(systemic	lupus	erythematosus).		Source:	Perez-Alamino,	R	et al, 201422	and	Ghetie	D,	et al, 2015. 23
chart 3: Cryoglobulinemia: Classification and Characteristics
Cryoglobulinemias Type I Type II Type III
Antibody	type Monoclonal IgM or IgG Polyclonal IgG and monoclonal 
IgM,	positive	RF
Polyclonal	IgG	and	IgM,	RF	
positive
Vascular	occlusive	
mechanism
Hyperviscosity Immune complex Immune complex
Comorbidities Hematological neoplasm (Type B lym-
phoproliferative disorders: Walden-
strom’s	macroglobulinemia,	multiple	
myeloma,	monoclonal	gammopathy)	
Hepatitis	C	or	B,	HIV,	autoim-
mune diseases 
Autoimmune	diseases	(Sjogren	
syndrome,	SLE,	rheumatoid	ar-
thritis),	hepatitis	C,	idiopathic.	
FIgure 3: a and b- Disseminated ecchymotic purpura in a male 
patient with meningoccocemia
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tension,	and/or	smoking.	11,32 Cholesterol embolisms are caused by 
atheromatous	plaque	fragmentation	secondary	to	a	force	that	causes	
plaque	 instability,	 such	as	 cardiac	catheterization,	prolonged	anti-
coagulation,	antithrombotic	therapy,	hemorrhage,	inflammation,	or	
infection.	The	 lesions	present	 in	hours,	days,	or	months.11,33 In to-
tal,	20%	of	cases	are	spontaneous.32 Manifestations are noted on the 
skin	in	35-88%	of	cases	as	well	as	in	the	kidneys	and	digestive	tract,	
with	a	variety	of	cutaneous	lesions,	such	as	livedo reticularis	in	40%,	
peripheral	 gangrene	 in	 35%,	 cyanosis	 in	 28%,	 ulceration	 in	 17%,	
nodules	in	10%,	and	purpura	in	9%,	along	with	malaise.11,32,34	Skin	
manifestations	 are	 bilateral	 and	 limited	 to	 the	 lower	 extremities,	
with normal peripheral pulses.33	Skin	biopsies	reveal	intravascular	
clefts	that	are	diagnostic	in	92%	of	cases	and	correspond	to	choles-
terol	crystals	that	dissolve	while	fixing	the	tissue.11,32 The condition 
carries	a	poor	prognosis	with	a	high	mortality	rate	(81%),	secondary	
to cardiac and renal complications.34 Treatment is supportive with 
aspirin,	statins,	prostacyclin	analogs,	discontinuation	of	anticoagu-
lation,	and	bypass	or	endarterectomy	in	special	cases.11 The use of 
systemic steroids is controversial.32,33 
Systemic coagulopathies 
Warfarin-induced necrosis 
This condition is due to abnormal γ-carboxylation of vita-
min	K-dependent	factors,	including	proteins	C	and	S,	leading	to	a	
hypercoagulable state in 24 to 48 hours.11,35,36 The condition mostly 
occurs	in	women	(4:1	ratio)	from	60	to	70	years	of	age,	especially	in	
patients	with	congenital	protein	C	deficiency.11,36	It	has	a	<	0.1%	inci-
dence	in	treated	patients,	presenting	in	90%	of	cases	approximately	
2 to 5 days after initiating treatment.35 Manifestations are apparent 
in	areas	of	subcutaneous	fat,	such	as	the	chest,	abdomen,	buttocks,	
and	thighs,	and	are	characterized	by	well-defined	painful	erythema	
that turns purplish and necrotic.11 Diagnosis is made by clinical sus-
picion	and	is	differentiated	from	hematoma,	disseminated	intravas-
cular	coagulation,	purpura fulminans,	 cellulitis,	and	calciphylaxis.37 
Histopathology	of	the	skin	shows	non-inflammatory	thrombosis	of	
dermal blood vessels.11 Treatment consists of the discontinuation of 
warfarin and administration of vitamin K. Heparin is administered 
in	cases	when	anticoagulation	is	needed,	and	protein	C	concentrates	
are also provided.35-37
Purpura fulminans
Purpura fulminans is a term used to describe any clinical 
presentation	 of	 disseminated	purpura	 (ecchymosis,	 palpable,	 and	
retiform)	in	septic	patients.	Neonatal,	acute,	and	idiopathic	presen-
tations have been described.38	Clinical	lesions	reflect	disseminated	
intravascular	coagulopathy	due	to	deficiency	or	dysfunction	of	coa-
gulation	factors	such	as	protein	C,	S,	or	antithrombin	III,	manifes-
ting	as	distal	symmetric	gangrene	(Figure	3).11	35,39 The lesions begin 
as	non-blanchable,	painful,	distal	purpuric	lesions	with	an	indura-
ted halo evolving into bullae that turn hemorrhagic and necrotic.39 
This purpura is mainly due to meningococcal infection but can be 
secondary to other bacterial or viral infections.11 Blood tests are con-
sistent with disseminated intravascular coagulation.11,38	Skin	biopsy	
reveals	fibrin	clots	in	dermal	vessels	with	some	inflammatory	infil-
trate.35	The	case-fatality	rate	is	high	at	50%,and	requires	multidisci-
plinary	 treatment	with	blood	and	coagulation	 factor	 transfusions,	
plasma	exchange	with	prednisone,	and	heparin	anticoagulation.11,38 
Antiphospholipid antibody syndrome 
Antiphospholipid	antibody	syndrome	(APS)	causes	cutane-
ous or systemic vessel occlusion due to anticardiolipin antibodies 
and circulating antiphospholipids that damage endothelial cells 
upon binding to exposed phospholipids and interfering with nor-
mal	procoagulant	protection,	leading	to	thrombosis.11 The condition 
affects	 the	skin	in	70%	of	cases,	presenting	as	a	variety	of	skin	le-
sions,	including	livedo reticularis	and	gangrene.	A	rare	catastrophic	
variant	 is	noted	 in	 1%	of	 cases	with	 a	 50%	mortality	 rate.11,40 The 
condition mainly affects women between 15 and 50 years of age.11 
Testing for anticardiolipin antibodies can be ordered upon suspi-
cion,	 and	anti-ß2	glycoproteins	are	more	 specific.	 In	addition,	 the	
lupus	anticoagulant	and	Venereal	Disease	Research	Laboratory	tests	
(VDRL)	show	positive	results.11,40	Histopathology	of	skin	lesions	re-
veals	non-inflammatory	thrombosis	of	dermal	vessels.41 Treatment 
is	 based	 on	 clinical	 history	 and	patient	 risk.	Anticoagulation	 and	
antiplatelet	drugs	are	administered	in	low-risk	patients,	and	high-
dose	 systemic	 steroids	 with	 anticoagulation,	 intravenous	 gamma	
globulin,	and	plasma	are	administered	in	high-risk	patients.40,42 
Others: Calciphylaxis 
Calciphylaxis,	also	known	as	calcifying	panniculitis	or	calci-
fic	uremic	arteriolopathy,	is	a	lethal	disease	that	affects	chronic	renal	
patients	on	hemodialysis	and	hyperparathyroidism	patients,	with	
80%	 case-fatality	 rate.11,	 43-45	Manifestations	 include	 calcification	 of	
the	arterial	midlayer	and	subintimal	fibrosis	followed	by	thrombotic	
occlusion.43	The	condition	affects	areas	such	as	abdomen,	buttocks,	
and	thighs,	with	varied	clinical	manifestations	including	livedo reti-
cularis,	plaques,	or	painful	violaceous	subcutaneous	nodules	with	
necrotic ulcers and eschar with superinfection in some cases (Figure 
4).44	Skin	biopsy	reveals	Von	Kossa-positive	calcium	deposits	in	the	
arterial	midlayer,	intimal	fibrosis,	and	intraluminal	thrombus	along	
with erythrocyte extravasation.45,46 Treatment should be aggressive 
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dium	thiosulfate	as	a	calcium	binder,	bisphosphonates,	cinacalcet,	
low-	calcium	dialysis,	hyperbaric	oxygen	therapy,	and	parathyroi-
dectomy.11,43,44	Steroids	are	spared	due	to	superinfection	risk	but	can	
be used in early-stage cases without necrosis.43,44 The diagnosis car-
ries a poor prognosis.
CONCLUSION
Purpura	 is	 one	 of	 the	 most	 frequent	 conditions	 seen	 in	
dermatology practice and covers a wide range of differential diag-
noses. It is important to consider all differential diagnoses and to 
know	their	basic	pathophysiology	because	treatment	varies	greatly	
according	 to	etiology,	despite	 the	 fact	 that	 the	biopsy	and	clinical	
manifestations	may	seem	very	similar.	Vasculitis	is	also	within	the	
spectrum	of	differentials.	However,	this	very	important	and	exten-
sive	topic	is	not	included	in	this	review,	but	we	should	not	forget	to	
take	this	condition	into	account	when	approaching	a	patient	with	
purpura. q
FIgure 4: Purpuric	plaques	with	necrosis	in	patient	with	calciphy-
laxis
and	include	metabolic	monitoring	of	calcium,	phosphate,	and	para-
thyroid	hormone	levels.	Treatment	is	based	on	phosphate	binders,	a	
phosphorus-free	diet,	discontinuation	of	vitamin	D,	and	antibiotics	
in case of superinfection.43 Other treatments include intravenous so-
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